Ivarmacitinib Sulfate Tablets

DRUG3 trials

Sponsors

Xiangya Hospital of Central South University, Peking University People's Hospital, Chinese SLE Treatment And Research Group

Conditions

Atopic Dermatitis (AD)Systemic Lupus Erthematosus

Phase 2

Ivarmacitinib Versus Glucocorticoids in Mild-to-Moderate Systemic Lupus Erythematosus

Not yet recruitingNCT07814664

Chinese SLE Treatment And Research GroupSystemic Lupus Erthematosus

Start: 2026-10-15End: 2028-09-30Target: 294Updated: 2026-09-11

Unknown Phase

Treatment of Moderate-to-Severe Atopic Dermatitis With Ivarmacitinib in Adolescents and Adults

Not yet recruitingNCT07276620

Xiangya Hospital of Central South UniversityAtopic Dermatitis (AD)

Start: 2025-11-30End: 2029-01-30Target: 1000Updated: 2025-12-11

Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to Interleukin-4 Receptor Alpha(IL-4Rα) Inhibitors: A Prospective, Multicenter, Real-World Study

Not yet recruitingNCT07550452

Peking University People's HospitalAtopic Dermatitis (AD)

Start: 2026-03-31End: 2027-07-31Target: 300Updated: 2026-04-24